Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Please stand by. Your meeting is about to begin. Good afternoon, ladies and gentlemen. Welcome to the Verica Pharmaceuticals second quarter 2026 corporate update conference call. At this time, all participants are in a listen-only mode. After the speaker's prepared remarks, there will be a question-and-answer session. To register to ask a question at any time, please press star 1 on your telephone. If you would like to remove yourself from the queue, please press star 2. As a reminder, this conference is being recorded. I would now like to turn the call over to our host, Mr. Kevin Gardner of LifeSci Advisors. Please go ahead, sir. Thank you, operator. Hello, everyone, and welcome to Verica Pharmaceuticals' second quarter 2026 corporate update conference call. With me on the line this evening are Jason Rieger, President and Chief Executive Officer, Noah Rosenberg, Chief Medical Officer, John Kirby, Interim Chief Financial Officer, David Zawitz, Chief Operating Officer, and Chris Chapman, Chief Commercial Officer. As a reminder during today's call, management will make forward-looking statements. These forward-looking statements are based on the company's current expectations and involve inherent risks and uncertainties. Verica's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements. Please see Verica's SEC filings for important risk factors. Verica cautions you not to place undue reliance on forward-looking statements and undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in expectations. In addition, during today's call, management will discuss certain non-GAAP financial measures. These non-GAAP financial measures are in...